Amgen Inc.’s Acquisition of Horizon Therapeutics plc
The FTC approves Amgen’s $28B purchase of Horizon.
In re HIV Antitrust Litigation
The jury found in favor of the defense concluding, consistent with Dr. Saravia’s testimony, that the settlement contained no payment for delay.
Federal Trade Commission v. 1-800 Contacts
The Second Circuit Court of Appeals overturned an FTC decision regarding trademark enforcement against online competitors.
Alleged Failure to Disclose Drug Safety Issues
Cornerstone Research was retained by a pharmaceutical company facing securities litigation after it withdrew a drug from the market because of safety concerns.
ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug
An ICC arbitration tribunal determined that the claimant did not materially breach its license agreement with the respondent, leaving the agreement in full effect.
In re Niaspan Antitrust Litigation
The judge denied class certification in this pharmaceutical pay-for-delay multidistrict litigation.
In re Intuniv Antitrust Litigation
The judge denied class certification in this pharmaceutical pay-for-delay case brought by a class of indirect purchasers.
Cigna’s Acquisition of Express Scripts
The parties completed a $67 billion merger after receiving clearance from the U.S. Department of Justice and state departments of insurance.
Hsu et al. v. Puma Biotechnology Inc. et al.
Positive jury verdict in rare securities class action trial.
Product Hopping
Pharmaceutical manufacturers have been accused of engaging in product hopping by introducing modified versions of branded drugs nearing patent expiry while simultaneously withdrawing the older drugs to hinder generic substitution.
How can we help you?
If you are looking for additional case experience examples, contact us.
